Ayla Gökmen
Research Subjects
Ayla Gökmen has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ugur Sahin
Department of Hematology, Ankara University Faculty of Medicine, Ankara, Türkiye
8 shared publications - Muhit Özcan
Ankara University School of Medicine, Ankara, Turkey
7 shared publications - Önder Arslan
Department of Hematology, School of Medicine, Ankara University, Ankara, Türkiye
7 shared publications - Ender Soydan5 shared publications
- Selin Merih Urlu
Hematology and Bone Marrow Transplantation Unit, Medicana International Ankara Hospital, Ankara, Türkiye
5 shared publications - Mevlüde Kurdal Okcu3 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 116-130
Allogeneic Hematopoietic Cell Transplantation for Relapsed/ Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience
AlloHCT remains a curative option for R/R Hodgkin lymphoma despite advances with BV and CPIs. This study evaluates its role and outcomes in this challenging patient population. This retrospective oligocentric analysis involved 70 patients with R/R classical HL who underwent alloHCT. Patients were split into two treatment cohorts: era1 (2004-2010), 16 patients, and era2 (2011-2021), 54 patients. Among the cohort, sixty-three patients had previously received an autologous stem cell transplant. Forty patients were administered only (n=29) BV or BV preceding CPI (n=11) before alloHCT. A median follow-up of 64 months (40.7-87.3) revealed a 100-day non-relapse mortality (NRM) rate of 26%, with the 3-year overall survival (OS) and progression-free survival (PFS) reported as 39% and 28%, respectively. AlloHCT using haplotype-matched donors was linked to better OS and PFS. Post-transplant cyclophosphamide (post-tx CY) as a prophylactic approach for graft versus host disease (GVHD) significantly improved OS and PFS. A complete response (CR) during the post-transplant phase significantly improved OS and PFS. Indeed, better OS, PFS, and a reduced rate of NRM were observed in the pre/post-alloHCT BV and CPI group, although we could not demonstrate statistical significance. The survival (OS, PFS) curves and NRM rates were similar for both eras. AlloHCT is a potentially practical therapeutic approach in responding to R/R HL patients.
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 116-130
Open AccessAllogeneic Hematopoietic Cell Transplantation for Relapsed/ Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience
AlloHCT remains a curative option for R/R Hodgkin lymphoma despite advances with BV and CPIs. This study evaluates its role and outcomes in this challenging patient population. This retrospective oligocentric analysis involved 70 patients with R/R classical HL who underwent alloHCT. Patients were split into two treatment cohorts: era1 (2004-2010), 16 patients, and era2 (2011-2021), 54 patients. Among the cohort, sixty-three patients had previously received an autologous stem cell transplant. Forty patients were administered only (n=29) BV or BV preceding CPI (n=11) before alloHCT. A median follow-up of 64 months (40.7-87.3) revealed a 100-day non-relapse mortality (NRM) rate of 26%, with the 3-year overall survival (OS) and progression-free survival (PFS) reported as 39% and 28%, respectively. AlloHCT using haplotype-matched donors was linked to better OS and PFS. Post-transplant cyclophosphamide (post-tx CY) as a prophylactic approach for graft versus host disease (GVHD) significantly improved OS and PFS. A complete response (CR) during the post-transplant phase significantly improved OS and PFS. Indeed, better OS, PFS, and a reduced rate of NRM were observed in the pre/post-alloHCT BV and CPI group, although we could not demonstrate statistical significance. The survival (OS, PFS) curves and NRM rates were similar for both eras. AlloHCT is a potentially practical therapeutic approach in responding to R/R HL patients.
- 6 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 468.e1-468.e14
Cladribine as an Alternative to Fludarabine in Melphalan and Total Body Irradiation-Based Reduced Intensity Conditioning
- 6 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 468.e1-468.e14
Cladribine as an Alternative to Fludarabine in Melphalan and Total Body Irradiation-Based Reduced Intensity Conditioning
- 28 April 2025
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 9 (1) , 14-20
AL Amiloidozda Otolog Kök Hücre Nakli ile Daratumumab Tabanlı İndüksiyon ve İdame Tedavilerinin Sağkalıma Etkisi
- 28 April 2025
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 9 (1) , 14-20
AL Amiloidozda Otolog Kök Hücre Nakli ile Daratumumab Tabanlı İndüksiyon ve İdame Tedavilerinin Sağkalıma Etkisi
- 3 December 2024
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 8 (3) , 92-97
Relaps Nodüler Lenfosit Predominant Hodgkin Lenfomada Kurtarma Tedavisi Sonrası Otolog Kök Hücre Nakli Sonuçları
- 3 December 2024
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 8 (3) , 92-97
Relaps Nodüler Lenfosit Predominant Hodgkin Lenfomada Kurtarma Tedavisi Sonrası Otolog Kök Hücre Nakli Sonuçları
- 22 August 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (2) , 51-56
Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Aseptik Nekroz Gelişen Olgularda Vitamin D Reseptör Gen Polimorfizmi
- 22 August 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (2) , 51-56
Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Aseptik Nekroz Gelişen Olgularda Vitamin D Reseptör Gen Polimorfizmi
- 25 August 2022
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 6 (2) , 56-66
Allojeneik Kök Hücre Nakli Sürecinde COVID-19 Sıklığı ve Seyri
- 25 August 2022
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 6 (2) , 56-66
Allojeneik Kök Hücre Nakli Sürecinde COVID-19 Sıklığı ve Seyri
- 1 July 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (10) , e885-e892
Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients
- 1 July 2022
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 22 (10) , e885-e892
Gemcitabine, Cisplatin, and Dexamethasone as a Salvage and Mobilization Chemotherapy Before Autologous Stem Cell Transplantation is Effective and Safe Outpatient Regimen in Relapsed and Refractory Hodgkin Lymphoma Patients
- 30 March 2022
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 6 (1) , 22-27
Relaps/Refrakter Akut Lenfoblastik Lösemide İnotuzumab Ozogamisin Tedavisi Sonrası Allojenik Kök Hücre Nakli Sonuçları
- 30 March 2022
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 6 (1) , 22-27
Relaps/Refrakter Akut Lenfoblastik Lösemide İnotuzumab Ozogamisin Tedavisi Sonrası Allojenik Kök Hücre Nakli Sonuçları
- 31 January 2020
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 4 (1) , 14-17
Vitamin D Deficiency and Outcomes in Adult Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation
- 31 January 2020
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 4 (1) , 14-17
Vitamin D Deficiency and Outcomes in Adult Acute Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation
- 10 December 2019
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 3 (3) , 51-54
Intensive Sequential Chemotherapy with Etoposide, Mitoxantrone and Ctarabine (EMA) as Salvage in Patients with Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation a Retrospective Analysis
- 10 December 2019
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 3 (3) , 51-54
Intensive Sequential Chemotherapy with Etoposide, Mitoxantrone and Ctarabine (EMA) as Salvage in Patients with Acute Myeloid Leukemia Relapsing After Allogeneic Stem Cell Transplantation a Retrospective Analysis